Desai Meena P
Hon. Consultant, B.J. Wadia Hospital for Children and Institute of Child Health and Research Centre - Endocrinology Division, Parel, and Hon. Pediatrician, Sir Hurkisondas Nurrotumdas Hospital and Research Centre, Raja Rammohan Roy Road, Mumbai, India.
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S153-5. doi: 10.4103/2230-8210.104027.
Primary sporadic congenital hypothyroidism (CH) is the most common cause of hypothyroidism infancy early childhood in iodine sufficient region. Screening for neonatal CH began in 1970s. The rationale and reason for neonatal screening for CH (NSCH) are well established. It is mandatory in most developed countries along with the screen for metabolic disorder. The possibility of measuring TSH and thyroid hormones in cord blood paved the way for newborn screening (NS) for CH. Worldwide it is estimated that 25% of the live born population of 130 million babies undergo NSCH. Klein et al., by 1972 had shown improved CNS prognosis in CH treated by age 3 months. NSCH has largely eradicated the severe irreversible neurodevelopmental damage and reversed the chances of growth failure in infancy and early childhood.
原发性散发性先天性甲状腺功能减退症(CH)是碘充足地区婴儿期和幼儿期甲状腺功能减退症最常见的病因。新生儿CH筛查始于20世纪70年代。新生儿CH筛查(NSCH)的基本原理和理由已得到充分确立。在大多数发达国家,NSCH与代谢紊乱筛查一样是强制性的。脐血中检测促甲状腺激素(TSH)和甲状腺激素的可能性为CH的新生儿筛查(NS)铺平了道路。据估计,全球1.3亿活产婴儿中有25%接受了NSCH。Klein等人在1972年表明,3个月龄前接受治疗的CH患儿中枢神经系统预后有所改善。NSCH在很大程度上消除了严重的不可逆神经发育损伤,并扭转了婴儿期和幼儿期生长发育迟缓的可能性。